IL-23通过STAT3表观遗传调控驱动狼疮患者Th17细胞扩增
研究探讨SLE中致病性Th17细胞的分子机制,发现IL-23诱导STAT3磷酸化并结合RORγT基因座,伴随H3K4me3增加和H3K27me3减少,促进Th17成熟;巴瑞替尼可浓度依赖性抑制该过程,SLE患者记忆Th17细胞pSTAT3呈超敏状态。
要点
- IL-23通过STAT3而非STAT4促进Th17细胞成熟。
- STAT3结合RORγT基因座并改变组蛋白修饰增强其表达。
- 巴瑞替尼抑制IL-23诱导的Th17扩增和pSTAT3。
核心结论
- IL-23/STAT3信号通过转录和表观遗传修饰在SLE患者Th17细胞成熟中起基础性作用,可能解释致病性Th17细胞扩增并提示新治疗靶点。
研究设计与样本
- 研究将naive CD4+ T细胞在Th17极化条件下培养5天,后以包括IL-23在内的多种细胞因子处理。
- 采用流式细胞术和定量PCR分析Th17标志物表达及STAT磷酸化,染色质免疫沉淀PCR评估组蛋白修饰。
- 分析SLE患者(n=28)血液样本的T细胞表型和pSTATs,并在SLE患者(n=12)中研究巴瑞替尼对记忆Th17细胞的影响。
主要发现
- IL-23刺激静息Th17细胞促进其成熟(P < 0.0001)。
- IL-23在Th17细胞成熟过程中诱导pSTAT3而非pSTAT4(P < 0.05)。
- IL-23诱导的STAT3直接结合RORγT基因座,伴随H3K4me3许可标记诱导和H3K27me3抑制标记减少,增强RORγT基因表达。
- 巴瑞替尼浓度依赖性抑制IL-23诱导的Th17细胞扩增和pSTAT3(P < 0.05)。
- SLE患者记忆Th17细胞中,IL-23刺激使pSTAT3超敏化,巴瑞替尼可抑制(P < 0.05)。
临床怎么用
- 巴瑞替尼可能通过抑制IL-23/STAT3通路减少致病性Th17细胞,为SLE治疗提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To elucidate the molecular mechanisms underlying pathogenic Th17 cells, we investigated the modulation of epigenetic modifications and its association with SLE. METHODS: Naive CD4+ T cells were cultured in Th17 polarizing conditions for 5 days and then treated with various cytokines, including IL-23. Expression of Th17 cell-related markers and phosphorylation of signal transducers and activators of transcription (pSTATs) were analysed using flow cytometry and quantitative PCR. Histone modifications were assessed using chromatin immunoprecipitation PCR. T cell phenotypes and pSTATs were analysed in blood samples of patients with SLE (n = 28). Finally, the effects of baricitinib on memory Th17 cells were investigated in SLE patients (n = 12). RESULTS: Stimulation of resting Th17 cells with IL-23 promoted maturation of these cells (P < 0.0001). IL-23 induced pSTAT3, but not pSTAT4, during Th17 cell maturation (P < 0.05). IL-23-induced STAT3 directly bound the RORγT gene locus. This was accompanied by induction of the H3H4me3 permissive mark and reduction of the H3K27me3 repressive mark, leading to enhanced RORγT gene expression. IL-23-induced expansion of Th17 cells and pSTAT3 were suppressed by the addition of baricitinib in a concentration-dependent manner (P < 0.05). In memory Th17 cells from SLE patients, pSTAT3 was hypersensitized by IL-23 stimulation and inhibited by baricitinib (P < 0.05). CONCLUSION: The results of this study indicate that IL-23/STAT3 signalling plays a fundamental role in Th17 cell maturation through transcriptional and epigenetic modifications in patients with SLE. This mechanism may underlie pathogenic Th17 cell expansion and may lead to identification of novel therapeutic targets for SLE.
引用
- Lee S, Nakayamada S, Kubo S, et al. Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology (Oxford). 2020. PMID: 32375179. doi:10.1093/rheumatology/keaa176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。